Avenzo
10 known investors
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments. The company focuses on oncology and cell therapy programs.
Founders & leadership
AC
Athena CountouriotisCo-Founder, Chief Executive Officer
Investors · 10
Delos CapitalCambridge
Foresite CapitalWest Hollywood
INCE CapitalShanghai
Longwood FundBoston
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
OrbiMedNew York · $1M – $75M
Quan CapitalShanghai
Sofinnova VenturesMenlo Park · $100K – $15M
SR One Capital ManagementRedwood City
NVIDIAreportedSanta Clara
Competitors · 2
by search overlapBioworld11 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Agenus11 shared keywordsAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Companies competing with Avenzo for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026Frequently asked questions
- What does Avenzo do?
- Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments. The company focuses on oncology and cell therapy programs.
- Who founded Avenzo?
- Avenzo was founded by Athena Countouriotis.
- Who are Avenzo's investors?
- Avenzo's investors include Delos Capital, Foresite Capital, INCE Capital, Longwood Fund, New Enterprise Associates (NEA), OrbiMed, Quan Capital, Sofinnova Ventures and 2 more.